Streetbeat News

Price Targets

MET

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on MetLife (NYSE:MET) and raises the price target from $82 to $83.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:24 pm

BTAI

Mizuho analyst Graig Suvannavejh has downgraded BioXcel Therapeutics from Buy to Neutral and lowered the price target from $40 to $4.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 12:24 pm

OGS

Stifel analyst Selman Akyol maintains a 'Hold' rating on ONE Gas (NYSE:OGS) and raises the price target from $81 to $82.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:23 pm

PRVA

TD Cowen analyst Gary Taylor has maintained an 'Outperform' rating on Privia Health Gr (NASDAQ:PRVA), but lowered the price target from $44 to $35.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:22 pm

LNC

Wells Fargo analyst Elyse Greenspan maintains an Equal-Weight rating on Lincoln National (NYSE:LNC) and raises the price target from $25 to $27.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:21 pm

GOL

Citigroup analyst Stephen Trent has downgraded Gol Intelligent Airlines (NYSE:GOL) from Buy to Neutral and set a price target of $4.2.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 12:20 pm

OPRX

Stifel analyst David Grossman has maintained a 'Buy' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $16 to $13.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:20 pm

EQH

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on Equitable Hldgs (NYSE:EQH) and raises the price target from $38 to $41.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:19 pm

DSGN

SVB Leerink analyst Joseph Schwartz has downgraded Design Therapeutics (NASDAQ:DSGN) from Outperform to Market Perform and set a price target of $6.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 12:18 pm

BTMD

TD Cowen analyst Brian Holland maintains an Outperform rating on Biote (NASDAQ:BTMD) but lowers the price target from $12 to $7.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:17 pm